Astellas Pharma Balance Sheet Health
Financial Health criteria checks 3/6
Astellas Pharma has a total shareholder equity of ¥1,596.0B and total debt of ¥920.0B, which brings its debt-to-equity ratio to 57.6%. Its total assets and total liabilities are ¥3,569.6B and ¥1,973.6B respectively. Astellas Pharma's EBIT is ¥86.9B making its interest coverage ratio 157.9. It has cash and short-term investments of ¥335.7B.
Key information
57.6%
Debt to equity ratio
JP¥920.02b
Debt
Interest coverage ratio | 157.9x |
Cash | JP¥335.69b |
Equity | JP¥1.60t |
Total liabilities | JP¥1.97t |
Total assets | JP¥3.57t |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ALPM.F's short term assets (¥1,194.7B) do not cover its short term liabilities (¥1,285.7B).
Long Term Liabilities: ALPM.F's short term assets (¥1,194.7B) exceed its long term liabilities (¥687.9B).
Debt to Equity History and Analysis
Debt Level: ALPM.F's net debt to equity ratio (36.6%) is considered satisfactory.
Reducing Debt: ALPM.F's debt to equity ratio has increased from 0.1% to 57.6% over the past 5 years.
Debt Coverage: ALPM.F's debt is not well covered by operating cash flow (18.7%).
Interest Coverage: ALPM.F's interest payments on its debt are well covered by EBIT (157.9x coverage).